-
1Academic Journal
Source: Наука и здравоохранение. :7-15
Subject Terms: ауырлық дәрежесі, predictive value, COVID-19, severity, факторы риска, жас, қауіп факторлары, болжамдық мән, 3. Good health, тяжесть течения, age, прогностическая значимость, risk factors, возраст
-
2Academic Journal
Authors: M. S. Sobolevskaya, A. D. Gvozdeva, O. N. Svirida, A. Y. Filatova, М. С. Соболевская, А. Д. Гвоздева, О. Н. Свирида, А. Ю. Филатова
Source: Medical Herald of the South of Russia; Том 15, № 4 (2024); 38-48 ; Медицинский вестник Юга России; Том 15, № 4 (2024); 38-48 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2024-15-4
Subject Terms: прогностическая значимость, preserved ejection fraction, left ventricular predictors, prognostic significance, сохраненная фракция выброса, левый желудочек, предикторы
File Description: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/1985/1062; Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. Erratum in: Circulation. 2022;145(18):e1033. Erratum in: Circulation. 2022;146(13):e185. Erratum in: Circulation. 2023;147(14):e674. https://doi.org/10.1161/CIR.0000000000001063; Tsao Cw, Aday Aw, Almarzooq ZI, Alonso A, Beaton AZ, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153-e639. Erratum in: Circulation. 2022;146(10):e141. https://doi.org/10.1161/CIR.0000000000001052.; Агеев Ф.Т., Овчинников А.Г. Лечение пациентов с сердечной недостаточностью и сохраненной фракцией выброса: опора на клинические фенотипы. Кардиология. 2022;62(7):44-53. https://doi.org/10.18087/cardio.2022.7.n2058; Iorio A, Senni M, Barbati G, Greene Sj, Poli S, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail. 2018;20(9):1257-1266. https://doi.org/10.1002/ejhf.1202; Kenchaiah S, Vasan RS. Heart Failure in women--Insights from the Framingham Heart Study. Cardiovasc Drugs Ther. 2015;29(4):377-390. https://doi.org/10.1007/s10557-015-6599-0; Huang R, wu R, Lin Y, Zhong X, Ye X, et al. Time-averaged cumulative blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: analysis from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. J Hypertens. 2022;40(10):1918-1926. https://doi.org/10.1097/HjH.0000000000003177; Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell GF, et al. Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction. Hypertension. 2021;77(2):546-556. https://doi.org/10.1161/HYPERTENSIONAHA.120.16277; Ovchinnikov A, Belyavskiy E, Potekhina A, Ageev F. Asymptomatic Leſt Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study. J Clin Med. 2022;11(13):3885. https://doi.org/10.3390/jcm11133885; Garg P, Assadi H, jones R, Chan WB, Metherall P, et al. Leſt ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep. 2021;11(1):617. https://doi.org/10.1038/s41598-020-79729-6; Shah AM, Cikes M, Prasad N, Li G, Getchevski S, et al. Echocardiographic Features of Patients with Heart Failure and Preserved Leſt Ventricular Ejection Fraction. J Am Coll Cardiol. 2019;74(23):2858-2873. https://doi.org/10.1016/j.jacc.2019.09.063; Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4(3):324-331. https://doi.org/10.1161/CIRCHEARTFAILURE.110.959890; Pandey A, Berry JD, Drazner MH, Fang JC, Tang WHW, Grodin JL. Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients with Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. J Am Heart Assoc. 2018;7(21):e009664. https://doi.org/10.1161/jAHA.118.009664; Voulgari C, Moyssakis I, Papazafiropoulou A, Perrea D, Kyriaki D, et al. The impact of metabolic syndrome on leſt ventricular myocardial performance. Diabetes Metab Res Rev. 2010;26(2):121-127. https://doi.org/10.1002/dmrr.1063; Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, et al. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. J Am Coll Cardiol. 2017;69(9):1129-1142. https://doi.org/10.1016/j.jacc.2016.11.081; MacDonald MR, Petrie MC, Varyani F, Ostergren j, Michelson EL, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-1385. https://doi.org/10.1093/eurheartj/ehn153; Kristensen SL, Mogensen UM, jhund PS, Petrie MC, Preiss D, et al. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients with Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure with Preserved Ejection Fraction). Circulation. 2017;135(8):724-735. https://doi.org/10.1161/CIRCULATIONAHA.116.024593; Bjorck LM, Lanitis M, Lappas G, Novak M, Rosengren A. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208. https://doi.org/10.1161/circ.125.suppl_10.AP208; Xie Z, Qi B, wang Z, Li F, Chen C, et al. Ablation for atrial fibrillation improves the outcomes in patients with heart failure with preserved ejection fraction. Europace. 2023;26(1):euad363. https://doi.org/10.1093/europace/euad363; Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved leſt ventricular function. Am Heart J. 2006;151(2):444-450. https://doi.org/10.1016/j.ahj.2005.03.066; Dalos D, Mascherbauer j, Zotter-Tufaro C, Duca F, Kammerlander AA, et al. Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol. 2016;68(2):189-199. https://doi.org/10.1016/j.jacc.2016.04.052; Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, et al. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245-254. https://doi.org/10.1016/j.jacc.2019.11.003; O'Meara E, de Denus S, Rouleau JL, Desai A. Circulating bio-markers in patients with heart failure and preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):350-358. https://doi.org/10.1007/s11897-013-0160-x; Solomon SD, McMurray JJV, Anand IS, Ge j, Lam CSP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609-1620. https://doi.org/10.1056/NEjMoa1908655; Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011;4(5):569-577. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962654; Jhund PS, Anand IS, Komajda M, Claggett BL, McKelvie RS, et al. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur J Heart Fail. 2015;17(8):809-817. https://doi.org/10.1002/ejhf.274; Luchner A, Behrens G, Stritzke J, Markus M, Stark K, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail. 2013;15(8):859-867. https://doi.org/10.1093/eurjhf/hſt048; Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, et al. Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134(1):73-90. https://doi.org/10.1161/CIRCULATIONAHA.116.021884; Okuyama R, Ishii J, Takahashi H, Kawai H, Muramatsu T, et al. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved leſt ventricular ejection fraction. Heart Vessels. 2017;32(7):880-892. https://doi.org/10.1007/s00380-017-0948-9; Pandey A, Golwala H, Sheng S, DeVore AD, Hernandez AF, et al. Factors Associated with and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure with Preserved Ejection Fraction: Findings From the American Heart Association Get with The Guidelines-Heart Failure Program. JAMA Cardiol. 2017;2(2):136-145. https://doi.org/10.1001/jamacardio.2016.4726; Pocock SJ, Ferreira JP, Gregson j, Anker SD, Butler J, et al. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(43):4455-4464. https://doi.org/10.1093/eurheartj/ehab579; Pocock SJ, Ferreira JP, Packer M, Zannad F, Filippatos G, et al. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur J Heart Fail. 2022;24(10):1869-1878. https://doi.org/10.1002/ejhf.2607; Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, et al. Biomarker Profiles in Heart Failure Patients with Preserved and Reduced Ejection Fraction. J Am Heart Assoc. 2017;6(4):e003989. https://doi.org/10.1161/jAHA.116.003989; Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35(6):1628-1637. https://doi.org/10.1016/s0735-1097(00)00582-9; Tromp J, westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, et al. Identifying Pathophysiological Mechanisms in Heart Failure with Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol. 2018;72(10):1081-1090. https://doi.org/10.1016/j.jacc.2018.06.050; Lakhani I, Wong MV, Hung JKF, Gong M, Waleed KB, et al. Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2021;26(5):1141-1150. https://doi.org/10.1007/s10741-020-09927-x; Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014;30(3):338-344. https://doi.org/10.1016/j.cjca.2013.12.010; Yin D, Yan X, Bai X, Tian A, Gao Y, Li J. Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction. ESC Heart Fail. 2023;10(2):1025-1034. https://doi.org/10.1002/ehf2.14271; Kleber ME, Koller L, Goliasch G, Sulzgruber P, Scharnagl H, et al. Von willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail. 2015;8(1):25-32. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001478; Naghipour S, Cox AJ, Peart JN, Du Toit EF, Headrick JP. Trimethylamine N-oxide: heart of the microbiota-CVD nexus? Nutr Res Rev. 2021;34(1):125-146. https://doi.org/10.1017/S0954422420000177; Dong Z, Zheng S, Shen Z, Luo Y, Hai X. Trimethylamine NOxide is Associated with Heart Failure Risk in Patients with Preserved Ejection Fraction. Lab Med. 2021;52(4):346-351. https://doi.org/10.1093/labmed/lmaa075; Salzano A, Israr MZ, Yazaki Y, Heaney LM, Kanagala P, et al. Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. Eur J Prev Cardiol. 2020;27(19):2159-2162. https://doi.org/10.1177/2047487319870355; Schuett K, Kleber ME, Scharnagl H, Lorkowski S, März w, et al. Trimethylamine-N-oxide and Heart Failure with Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol. 2017;70(25):3202-3204. https://doi.org/10.1016/j.jacc.2017.10.064; Kinugasa Y, Nakamura K, Kamitani H, Hirai M, Yanagihara K, et al. Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction. ESC Heart Fail. 2021;8(3):2103-2110. https://doi.org/10.1002/ehf2.13290; Abdelaziz Mohamed I, Gadeau AP, Hasan A, Abdulrahman N, Mraiche F. Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis. Cells. 2019;8(12):1558. https://doi.org/10.3390/cells8121558; Rosenberg M, Zugck C, Nelles M, juenger C, Frank D, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1(1):43-49. https://doi.org/10.1161/CIRCHEARTFAILURE.107.746172; Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fi-brogenesis. Circ Heart Fail. 2013;6(1):107-117. https://doi.org/10.1161/CIRCHEARTFAILURE.112.971168; Wu CK, Su MY, Lee JK, Chiang FT, Hwang JJ, et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep. 2015;5:17007. https://doi.org/10.1038/srep17007; van Kimmenade RR, januzzi JL Jr, Ellinor PT, Sharma UC, Bakker jA, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217-1224. https://doi.org/10.1016/j.jacc.2006.03.061; Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12(8):826-832. https://doi.org/10.1093/eurjhf/hfq091; Vianello E, Dozio E, Tacchini L, Frati L, Corsi Romanelli MM. ST2/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019;116:105619. https://doi.org/10.1016/j.biocel.2019.105619; O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, et al. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients with Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018;11(5):e004446. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004446; Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved leſt ventricular ejection fraction. Clin Chem. 2011;57(6):874-882. https://doi.org/10.1373/clinchem.2010.159277; Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the leſt ventricle. N Engl J Med. 2004;350(19):1953-1959. https://doi.org/10.1056/NEjMoa032566; Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, et al. wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935-944. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001229; Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35(44):3103-3112. https://doi.org/10.1093/eurheartj/ehu315; Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588-595. https://doi.org/10.1161/CIRCHEARTFAILURE.109.930701; Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation. 2017;135(9):825-838. https://doi.org/10.1161/CIRCULATIONAHA.116.024822; Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297-3317. Erratum in: Eur Heart J. 2021;42(13):1274. https://doi.org/10.1093/eurheartj/ehz641; Holland DJ, Prasad SB, Marwick TH. Prognostic implications of leſt ventricular filling pressure with exercise. Circ Cardiovasc Imaging. 2010;3(2):149-156. https://doi.org/10.1161/CIRCIMAGING.109.908152; Shim CY, Kim SA, Choi D, Yang WI, Kim JM, et al. Clinical outcomes of exercise-induced pulmonary hypertension in subjects with preserved leſt ventricular ejection fraction: implication of an increase in leſt ventricular filling pressure during exercise. Heart. 2011;97(17):1417-1424. https://doi.org/10.1136/hrt.2010.220467; Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016;37(43):3293-3302. https://doi.org/10.1093/eurheartj/ehw241; Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009;54(1):36-46. https://doi.org/10.1016/j.jacc.2009.03.037; Kosmala w, Przewlocka-Kosmala M, Rojek A, Mysiak A, Dabrowski A, Marwick TH. Association of Abnormal Leſt Ventricular Functional Reserve with Outcome in Heart Failure with Preserved Ejection Fraction. JACC Cardiovasc Imaging. 2018;11(12):1737-1746. https://doi.org/10.1016/j.jcmg.2017.07.028; Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. https://doi.org/10.1038/nrcardio.2014.83; Ovchinnikov AG, Potekhina A, Belyavskiy E, Gvozdeva A, Ageev F. Leſt atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndrome. J Clin Ultrasound. 2022;50(8):1073-1083. https://doi.org/10.1002/jcu.23318; Morris DA, Belyavskiy E, Aravind-Kumar R, Kropf M, Frydas A, et al. Potential Usefulness and Clinical Relevance of Adding Leſt Atrial Strain to Leſt Atrial Volume Index in the Detection of Leſt Ventricular Diastolic Dysfunction. JACC Cardiovasc Imaging. 2018;11(10):1405-1415. https://doi.org/10.1016/j.jcmg.2017.07.029; Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245-257. https://doi.org/10.1016/j.jcmg.2018.12.034; Santos AB, Roca Gq, Claggett B, Sweitzer NK, Shah SJ, et al. Prognostic Relevance of Leſt Atrial Dysfunction in Heart Failure with Preserved Ejection Fraction. Circ Heart Fail. 2016;9(4):e002763. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002763; Guazzi M. Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives. Circ Heart Fail. 2014;7(2):367-377. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000823; Hidalgo C, Granzier H. Tuning the molecular giant titin through phosphorylation: role in health and disease. Trends Cardiovasc Med. 2013;23(5):165-171. https://doi.org/10.1016/j.tcm.2012.10.005; Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic leſt ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol. 2015;65(3):257-266. https://doi.org/10.1016/j.jacc.2014.10.044; Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119-1126. https://doi.org/10.1016/j.jacc.2008.11.051; Mohammed SF, Hussain I, AbouEzzeddine OF, Takahama H, Kwon SH, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation. 2014;130(25):2310-2320. Erratum in: Circulation. 2015;131(17):e424. doi:10.1161/CIR.0000000000000202. Abou Ezzeddine, Omar F [corrected to AbouEzzeddine, Omar F]. https://doi.org/10.1161/CIRCULATIONAHA.113.008461; Ovchinnikov A, Potekhina A, Belyavskiy E, Ageev F. Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors. Pharmaceuticals (Basel). 2022;15(8):1024. https://doi.org/10.3390/ph15081024; Huang W, Oliveira RKF, Lei H, Systrom DM, Waxman AB. Pulmonary Vascular Resistance During Exercise Predicts Long-Term Outcomes in Heart Failure with Preserved Ejection Fraction. J Card Fail. 2018;24(3):169-176. https://doi.org/10.1016/j.cardfail.2017.11.003; Gorter TM, Hoendermis ES, van Veldhuisen Dj, Voors AA, Lam CS, et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2016;18(12):1472-1487. https://doi.org/10.1002/ejhf.630; Melenovsky V, Hwang Sj, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3452-3462. https://doi.org/10.1093/eurheartj/ehu193; Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol. 2013;305(9):H1373-81. https://doi.org/10.1152/ajpheart.00157.2013; Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288-299. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000854; Ovchinnikov A, Filatova A, Sobolevskaya M, Potekhina A, Svirida O, et al. The prognostic role of cardiac hemodynamic reserves in heart failure with preserved ejection fraction. Journal of Hypertension. 2024;42(Suppl 1):p e242. https://doi.org/10.1097/01.hjh.0001021964.41256.b4; https://www.medicalherald.ru/jour/article/view/1985
-
3Academic Journal
Authors: Yakunina E.Y., Kovaleva O.V., Zukov R.A., Gratchev A.N., Salamatin S.S., Kochkina S.O., Mammadli Z.Z., Kushlinskii N.E.
Contributors: 1
Source: Almanac of Clinical Medicine; Vol 52, No 6 (2024); 324-330 ; Альманах клинической медицины; Vol 52, No 6 (2024); 324-330 ; 2587-9294 ; 2072-0505
Subject Terms: colorectal cancer, galectin-4, serum, prognostic relevance, колоректальный рак, галектин-4, сыворотка крови, прогностическая значимость
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/17362/1698; https://almclinmed.ru/jour/article/view/17362/1701; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160222; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160223; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160224; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160225; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160226; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160227; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160228; https://almclinmed.ru/jour/article/downloadSuppFile/17362/160229; https://almclinmed.ru/jour/article/view/17362
-
4Academic Journal
Authors: A. G. Polupanov, A. U. Mamatov, M. T. Duishenalieva, A. T. Аrykova, F. T. Rysmatova, I. Kh. Bebezov, S. M. Akhunbaev, I. S. Sabirov, A. S. Dzhumagulova, А. Г. Полупанов, А. У. Маматов, М. Т. Дуйшеналиева, А. Т. Арыкова, Ф. Т. Рысматова, И. Х. Бебезов, С. М. Ахунбаев, И. С. Сабиров, А. С. Джумагулова
Source: Acta Biomedica Scientifica; Том 6, № 5 (2021); 245-252 ; 2587-9596 ; 2541-9420
Subject Terms: прогностическая значимость, risk factors, cardiovascular complications, survival, gender and age differences, prognostic value, факторы риска, сердечно-сосудистые осложнения, выживаемость, гендерные возрастные различия
File Description: application/pdf
Relation: https://www.actabiomedica.ru/jour/article/view/3057/2238; World Health Organization. 10 facts about obesity. 2017; 1-10.; Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377(9765): 557-567. doi:10.1016/ S0140-6736(10)62037-5; Souza SA, Silva AB, Cavalcante UMB, Lima CMBL, de Souza TC. Adult obesity in different countries: an analysis via beta regression models. Cad Saude Publica. 2018; 34(8): e00161417. doi:10.1590/0102-311X00161417; Katz D, Friedman R. Diet, weight regulation, and obesity. In: Nutrition in clinical practice. 2nd ed. Philadelphia: Lippincott Williams&Wilkins. 2008.; Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008; 32(9): 1431-1437. doi:10.1038/ijo.2008.102; Романова Т.А., Нышанова С.Т., Полупанов А.Г., Халматов А.Н. Распространённость артериальной гипертонии и других факторов риска сердечно-сосудистых заболеваний в популяции сельских жителей Кыргызстана. Профилактика заболеваний и укрепление здоровья. 2007; 3: 14-17.; Джумагулова А.С., Полупанов А.Г., Халматов А.Н., Алтымышева А.Т., Маматов А.У., Романова Т.А. Гендерные и этнические особенности распространённости ожирения среди жителей малых городов и сельской местности Кыргызской Республики (по данным исследования «Интерэпид»). Кардиологический вестник. 2019; 2: 61-66. doi:10.17116/ Cardiobulletin20191402161 8. Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. Obes Rev. 2007; 8(1): 41-59. doi:10.1111/j.1467-789X.2006.00248.x; Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all-cause mortality: Systematic review and nonlinear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016; 353: i2156.35. doi:10.1136/bmj.i2156; Barry V, Baruth M, Beets M, Durstine JL, Liu J, Blair SN. Fitness vs. fatness on all-cause mortality: A meta-analysis. Prog Cardiovasc Dis. 2014; 56(4): 382-390. doi:10.1016/j.pcad.2013.09.002; Hansel B, Roussel R, Elbez Y, Marre M, Krempf M, Ikeda Y, et al. Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. Eur Heart J. 2015; 36(40): 2716-2728. doi:10.1093/eurheartj/ehv347; Полупанов А.Г., Концевая А.В., Халматов А.Н., Алтымышева А.Т., Суворова Е.Т., Романова Т.А. и др. Распространённость артериальной гипертензии среди жителей малых городов и сельской местности Кыргызской Республики: этнические особенности (по данным международного исследования «Интерэпид»). Кардиоваскулярная терапия и профилактика. 2013; 12(6): 4-8. doi:10.15829/1728-8800-2013-6-4-8; Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju S, Wormser D, Gao P, Kaptoge S, et al. Body-mass index and all-cause mortality: Individual participant-data metaanalysis of 239 prospective studies in four continents. Lancet. 2016; 388(10046): 776-786. doi:10.1016/S0140-6736(16)30175-1; Ni Mhurchu C, Rodgers A, Pan WH, Gu DF, Woodward M, Asia Pacific Cohort Studies Collaboration. Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol. 2004; 33(4): 751-758. doi:10.1093/ije/dyh163; Liao W, Luo Z, Hou Y. Cui N, Liu X, Huo W, et al. Age and gender specific association between obesity and depressive symptoms: A large-scale cross-sectional study. BMC Public Health. 2020; 20(1): 1565. doi:10.1186/s12889-020-09664-8; Hosseini Z, Veenstra G, Khan NA, Conklin AI Associations between social connections, their interactions, and obesity differ by gender: A population-based, cross-sectional analysis of the Canadian Longitudinal Study on Aging. PLoS ONE. 2020; 15(7): e0235977. doi:10.1371/journal.pone.0235977; Tsao YC, Lee YY, Chen JY, Yeh WC, Chuang CH, Yu W, et al. Gender- and age-specific associations between body fat composition and C-reactive protein with lung function: A cross-sectional study. Sci Rep. 2019; 9(1): 384. doi:10.1038/s41598-018-36860-9; Tsao YC, Chen JY, Yeh WC, Li WC. Gender- and age-specific associations between visceral obesity and renal function impairment. Obes Facts. 2019; 12(1): 67-77. doi:10.1159/000496626; Wang Q, Xu L, Li J, Sun L, Qin W, Ding G, et al. Association of anthropometric indices of obesity with hypertension in Chinese elderly: An analysis of age and gender differences. Int J Environ Res Public Health. 2018; 15(4): 801. doi:10.3390/ijerph15040801; https://www.actabiomedica.ru/jour/article/view/3057
-
5Academic Journal
Source: Якутский медицинский журнал. 2021. № 4. С. 47-52
Subject Terms: прогностическая значимость лабораторных тестов, дабигатрана этексилат, фармакодинамика, регуляция агрегатного состояния крови, чувствительность лабораторных тестов, гемокоагуляция, лабораторные тесты
File Description: application/pdf
-
6Academic Journal
Authors: Babushkina N.P., Bragina E.Y.
Source: Russian Journal of Infection and Immunity; Vol 11, No 2 (2021); 209-222 ; Инфекция и иммунитет; Vol 11, No 2 (2021); 209-222 ; 2313-7398 ; 2220-7619
Subject Terms: tuberculosis, genetic susceptibility, gene expression, immune response, prognostic significance, biomarker, туберкулез, генетическая подверженность, экспрессия генов, иммунный ответ, прогностическая значимость, биомаркер
File Description: application/pdf
Relation: https://iimmun.ru/iimm/article/view/1289/1199; https://iimmun.ru/iimm/article/downloadSuppFile/1289/4160; https://iimmun.ru/iimm/article/downloadSuppFile/1289/4161; https://iimmun.ru/iimm/article/downloadSuppFile/1289/4162; https://iimmun.ru/iimm/article/downloadSuppFile/1289/4163; https://iimmun.ru/iimm/article/downloadSuppFile/1289/4457; https://iimmun.ru/iimm/article/view/1289
-
7Academic Journal
Authors: Хлынова, О. В., Шишкина, Е. А., Зубова, М. А., Абгарян, Н. И.
Subject Terms: медицина, внутренние болезни, болезни сердца, инфаркт миокарда, молодой возраст, коморбидность, гендерные особенности, прогностическая значимость
Availability: http://dspace.bsu.edu.ru/handle/123456789/45886
-
8Academic Journal
Authors: Belaya, I.Ye., Kolomiets, V.I., Manischenkova, Yu.О.
Source: EMERGENCY MEDICINE; № 5.100 (2019); 84-89
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 5.100 (2019); 84-89
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 5.100 (2019); 84-89Subject Terms: острый период инфаркта миокарда, векторкардиограмма, чувствительность, специфичность, прогностическая значимость, acute phase of myocardial infarction, vectorcardiogram, sensitivity, specificity, prognostic significance, гострий період інфаркту міокарда, векторкардіограма, чутливість, специфічність, прогностична значущість
File Description: application/pdf
-
9Academic Journal
Authors: A. V. Boyarkina, A. L. Potapov, А. В. Бояркина, А. Л. Потапов
Source: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 12, № 5 (2015); 71-75 ; Вестник анестезиологии и реаниматологии; Том 12, № 5 (2015); 71-75 ; 2541-8653 ; 2078-5658
Subject Terms: area under curve, combined test, sensitivity, specificity, prognostic value, ROC-curve, комбинированный тест, чувствительность, специфичность, прогностическая значимость, ROC-кривая, площадь под ROC-кривой, diagnostic value
File Description: application/pdf
Relation: https://www.vair-journal.com/jour/article/view/55/56; Бояркина А. В. Влияние психологических и генетических факторов на эффективность послеоперационной аналгезии опиоидами: Дис. … канд. мед. наук: 14.01.20. - СПб., 2015. - 137 с. http://szgmu.ru/ds/upload/files/ Диссертация Бояркина.pdf; Паклин Н. Логистическая регрессия и ROC-анализ - математический аппарат [Электрон. ресурс]. - 2015. - Режим доступа: http://basegroup.ru/community/articles/logistic; Altman D. G., Bland J. M. Diagnostic tests 1: sensitivity and specificity // BMJ. - 1994. - Vol. 308 (6943). - P. 1552.; Altman D. G., Bland J. M. Diagnostic tests 2: predictive values // BMJ. - 1994. - Vol. 309 (6947). - P. 102.; DeLong E. R., DeLong D. M., Clarke-Pearson D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach // Biometrics. - 1988. - Vol. 44, № 3. - P. 837-845.; Hanley J. A., McNeil B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve // Radiology. - 1982. - Vol. 143, № 1. - P. 29-36.; Sommer M., de Rijke J. M., van Kleef M. et al. The prevalence of postoperative pain in a sample of 1490 surgical inpatients // Eur. J. Anaesthesiol. - 2008. - Vol. 25, № 4. - P. 267-274.; Parikh R., Mathai A., Parikh S. et al. Understanding and using sensitivity, specificity and predictive values // Indian. J. Ophthalmol. - 2008. - Vol. 56, № 1. - P. 45-50.; Weinstein S., Obuchowski N. A., Lieber M. L. Clinical evaluation of diagnostic tests // Am. J. Roentgenol. - 2005. - Vol. 184, № 1. - P. 14-19.; Zhou X. H., Obuchowski N. A., Mcclish D. K. Statistical methods in diagnostic medicine // Biometrics. - 2003. - Vol. 59, № 1. - P. 203-204.; Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine // Clin. Chem. - 1993. - Vol. 39, № 4. - P. 561-577.
-
10Academic Journal
Authors: БЛИНОВА ТАТЬЯНА ВЛАДИМИРОВНА, РАХМАНОВ РОФАИЛЬ САЛЫХОВИЧ, СТРАХОВА ЛАРИСА АНАТОЛЬЕВНА, КОЛЕСОВ СЕРГЕЙ АЛЕКСЕЕВИЧ
File Description: text/html
-
11Academic Journal
Authors: Shurkevich, N. P., Vetoshkin, A. S., Gapon, L. I., Shipitsyna, N. V., Gubin, D. G., Poshinov, F. A., Шуркевич, Н. П., Ветошкшг, А. С., Гапон, Л. И., Шипицына, Н. В., Губин, Д. Г., Пошинов, Ф. А.
Subject Terms: ATYPICAL NORMOTENSIVE CHRONOTYPES BLOOD PRESSURE BP, PROGNOSTIC SIGNIFICANCE, FAR NORTH, АТИПИЧНЫЕ НОРМОТЕНЗИВНЫЕ ХРОНОТИПЫ АД, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ, КРАЙНИЙ СЕВЕР
File Description: application/pdf
Relation: Уральский медицинский журнал. 2015. T. 128, № 5.; http://elib.usma.ru/handle/usma/14625
Availability: http://elib.usma.ru/handle/usma/14625
-
12Academic Journal
Authors: КУРИЛОВИЧ С.А., РЕШЕТНИКОВ О.В.
Subject Terms: CAGA-ПОЗИТИВНОСТЬ, СИНДРОМ ДИСПЕПСИИ, АТРОФИЧЕСКИЙ ГАСТРИТ, РАСПРОСТРАНЕННОСТЬ, ФАКТОРЫ РИСКА, НЕИНВАЗИВНАЯ ДИАГНОСТИКА, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ
File Description: text/html
-
13Academic Journal
Authors: ХАРИТОНОВ В.И.
File Description: text/html
-
14Academic Journal
Source: Медицинский альманах.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, С-РЕАКТИВНЫЙ БЕЛОК,ЛИЦА РАЗНОГО ВОЗРАСТА,РЕФЕРЕНТНЫЕ ВЕЛИЧИНЫ,КРИТЕРИИ РИСКА КАРДИОВАСКУЛЯРНОЙ ПАТОЛОГИИ,ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ,C-REACTIVE PROTEIN,INDIVIDUALS OF DIFFERENT AGE,REFERENCE VALUES,CRITERIA RISK OF CARDIOVASCULAR DISEASE,PROGNOSTIC VALUE, 3. Good health
File Description: text/html
-
15Academic Journal
Authors: Шишкин, Павел
Subject Terms: АДАПТАЦИОННЫЕ И ДИЗАДАПТАЦИОННЫЕ ПРОЦЕССЫ, ЭЛЕКТРОПУНКТУРНАЯ ДИАГНОСТИКА, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ, АНАЛИЗ ОЗДОРОВИТЕЛЬНОЙ ЭФФЕКТИВНОСТИ
File Description: text/html
-
16Academic Journal
Authors: Плотников, Анатолий, Чернышенко, Юрий
Subject Terms: ТЕХНОЛОГИИ ОТБОРА ЮНЫХ СПОРТСМЕНОВ, КРИТЕРИИ ПЕРСПЕКТИВНОСТИ, ПОКАЗАТЕЛИ ФИЗИЧЕСКОГО РАЗВИТИЯ, ИНФОРМАТИВНОСТЬ, СТАБИЛЬНОСТЬ, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ ИСХОДНОГО УРОВНЯ РАЗВИТИЯ ПОКАЗАТЕЛЕЙ, YOUNG ATHLETE'S SELECTION TECHNOLOGY
File Description: text/html
-
17Academic Journal
Authors: Молочков, В., Ковригина, А., Молочков, А., Караулов, А., Меньщикова, Г., Федоровская, А., Ефимович, И.
Subject Terms: Т-КЛЕТОЧНАЯ ЛИМФОМА КОЖИ, ГРИБОВИДНЫЙ МИКОЗ, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ, ПРОГНОСТИЧЕСКИЕ ФАКТОРЫ, ПРОГНОСТИЧЕСКИЙ ИНДЕКС, ИНДЕКС ТЯЖЕСТИ, СИНДРОМ СЕЗАРИ, SEZARY 'S SYNDROME, ВЫЖИВАЕМОСТЬ
File Description: text/html
-
18Academic Journal
Authors: M. V. Peters, V. E. Shevchenko, V. B. Matveev, M. I. Volkova, S. A. Kalinin, D. M. Mikhailenko, D. V. Zaletayev, М. В. Петерс, В. Е. Шевченко, В. Б. Матвеев, М. И. Волкова, С. А. Калинин, Д. М. Михайленко, Д. В Залетаев
Source: Cancer Urology; Том 7, № 4 (2011); 24-31 ; Онкоурология; Том 7, № 4 (2011); 24-31 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-4
Subject Terms: прогностическая значимость, VHL gene alterations, plasma markers, prognostic value, альтерации гена VHL, плазменные маркеры
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/185/199; Wood C.G. Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome. Clin Cancer Res 2007; 13(Suppl 2):697−702.; Херрингтон С., Макги Дж. Молекулярная клиническая диагностика. Пер. с англ. М.: Мир,1999. 558 с.; Hansel D.E., Rini B.I. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Reviews in Anticancer Therapy 2008; 8:895−905.; Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163−72.; Linehan W.M., Zbar B., Klausner R.D. The genetic basis of human cancer, chapter 27 (Renal carcinoma). 2nd ed. USA.: McGraw-Hill Companies, 2002.; Smits K.M., Schouten L.J., Dijk B.A. et al. Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008;14:782−7.; Gallou C., Joly D., Mejean A. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999; 13: 464–75.; Choueiri T.K., Vaziri S.A.J., Jaeger E. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180(3):860−5.; Rini B.I., Jaeger E., Weinberg V. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU International. 2006 Oct 1; 98(4):756−62.; Hutson T., Davis I.D., Macheils J.H. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26.; Kim J.H., Jung C.W., Cho Y.H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005;13: 859−64.; Van Houwelingen K.P., van Dijk B.A., Hulsbergen-van de Kaa C.A. et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results fromTheNetherlands Cohort Study. BMCCancer 2005;5:57.; Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6):669−76.; Rioux-Leclercq N., Fergelot P., Zerrouki S. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10):1489−95.; Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343−7.; Klatte T., Böhm M., Nelius T. et al. Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU International. 2007;100(1):209−14.; Negrier S., Perol D., Menetrier-Caux C. et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6−from the Groupe Francais d’Immunotherapie. J Clin Oncol 2004 Jun 15; 22(12):2371−8.; Alamdari F.I., Rasmuson T., Grankvist K., Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scandinavian journal of urology and nephrology 2007;41(1):5−9.; Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51(1):168−73.; Deprimo S.E., Bello C.L., Smeraglia J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.; Rini B.I., Michaelson M.D., Rosenberg J.E. et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26(22):3743−8.; Escudier B., Eisen T., Stadler WM. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312−8.; https://oncourology.abvpress.ru/oncur/article/view/185
-
19Academic Journal
Authors: Петерс, М., Шевченко, В., Матвеев, В., Волкова, М., Калинин, С., Михайленко, Д., В ЗАЛЕТАЕВ Д.
Subject Terms: ТАРГЕТНАЯ ТЕРАПИЯ, АЛЬТЕРАЦИИ ГЕНА VHL, ПЛАЗМЕННЫЕ МАРКЕРЫ, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ
File Description: text/html
-
20Academic Journal
Authors: Tesikov, Y., Lipatov, I., Melnikov, V., Salov, V., Mineeva, E., Anpilogova, I., Melikbekjan, A., Valeeva, G., Тезиков, Ю. В., Липатов, И. С., Мельников, В. А., Салов, В. В., Минеева, Е. Л., Анпилогова, И. В., Меликбекян, А. С., Валеева, Г. Р.
Subject Terms: PLACENTAL FAILURE, DIAGNOSTICS, PROGNOSTIC SIGNIFICANCE, ПЛАЦЕНТАРНАЯ НЕДОСТАТОЧНОСТЬ, ДИАГНОСТИКА, ПРОГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2009. Т. 57, № 3.; http://elib.usma.ru/handle/usma/16521
Availability: http://elib.usma.ru/handle/usma/16521
